Table 2.

Adverse events possibly, probably, or definitely related to nintedanib. Percentages are of the total number of patients (32).

	Grade 1 n (%)	Grade 2 n (%)	Grade 3 n (%)	Grade 4 n (%)
Abdominal pain	1 (3)	0	0	0
Anemia	2 (6)	0	0	0
Anorexia	3 (9)	1 (3)	0	0
Blood bilirubin increased	3 (9)	0	0	0
Constipation	2 (6)	0	0	0
Diarrhea	15 (47)	1 (3)	0	0
Dry mouth	1 (3)	0	0	0
Dyspepsia	1 (3)	0	0	0
Fatigue	16 (50)	3 (9)	1 (3)	0
Flatulence	1 (3)	0	0	0
Hypertension	11 (34)	12 (37.5)	5 (16)	0
Hypertriglyceridemia	0	0	1 (3)	1 (3)
LFT abnormalities	29 (91)	9 (28)	2 (6)	0
Lymphocyte count decreased	1 (3)	0	1 (3)	0
Melena	1 (3)	0	0	0
Nausea	8 (25)	4 (12.5)	0	0
Oral mucositis	1 (3)	1 (3)	0	0
Platelet count decreased	5 (16)	0	0	0
Pruritus	1 (3)	0	0	0
Dry skin	1 (3)	0	0	0
Thromboembolic event	0	0	1 (3)	0
Vomiting	4 (12.5)	0	0	0
Weight loss	1 (3)	0	0	0
White blood cell count decreased	3 (9)	0	0	0

LFT, liver function test.